On Thursday, November 19, Johns Hopkins Bloomberg School of Public Health will host a webinar with key experts to discuss what leaders and individuals can do to reverse current troubling COVID-19 trends.

As the U.S. enters the most challenging phase of the pandemic to date, states are reimposing different kinds of mitigation measures. This time around, experts are offering a wider range of solutions.

More than 1 in every 400 people tested positive in the past week, and rising deaths have pushed even some reluctant governors to issue mask mandates and to limit gatherings.

Hopkins experts Jennifer Nuzzo and Josh Sharfstein on the challenges communities will face to distribute a COVID-19 vaccine to everybody.

Pfizer’s promising COVID-19 vaccine must be stored at about -94° F—a temperature that only specialized freezers can produce. Those cold storage requirements are raising serious questions about who could get the Pfizer vaccine if it’s approved, and when.

Dr. William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health, provides a coronavirus vaccine update.

The Johns Hopkins University SAIS Reischauer Center’s virtual conference with the T-20 Global Think Tank Summit will consider topics of global importance, including lessons for the international community from East Asia’s initial response to COVID-19.

Contact tracing apps have made slow progress across the country, hampered by sluggish and uncoordinated development, distrust of technology companies, and inadequate advertising budgets and messaging campaigns.

Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja on delivery of a coronavirus vaccine and the potential for improving on initial COVID-19 vaccines.

Dr. Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security, on why while it is appropriate to be very enthusiastic about Pfizer's vaccine development, it must be tempered to some degree. 

The U.S. government has spent more than $10 billion creating vaccines to protect against COVID-19 but so far little encouraging Americans to take them. Public health officials say that's a mistake.

Joshua Sharfstein of the Johns Hopkins Bloomberg School of Public Health on why Pfizer’s coronavirus vaccine still needs to go through regulatory review for safety.